These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1176 related items for PubMed ID: 26069923

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM, Han GH.
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [Abstract] [Full Text] [Related]

  • 4. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY.
    Int J Cancer; 2015 Mar 15; 136(6):1458-67. PubMed ID: 25099027
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y, Chen B, Liu N, Li N, Dao H, Chen W, Yang J.
    Int J Clin Pharmacol Ther; 2017 Jun 15; 55(6):498-508. PubMed ID: 28157070
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O.
    Oncology; 2014 Jun 15; 87(6):330-41. PubMed ID: 25227534
    [Abstract] [Full Text] [Related]

  • 9. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W.
    Radiology; 2012 May 15; 263(2):590-9. PubMed ID: 22438359
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
    Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC.
    Radiology; 2013 Nov 15; 269(2):603-11. PubMed ID: 23864102
    [Abstract] [Full Text] [Related]

  • 11. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 15; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF.
    J Clin Oncol; 2011 Oct 20; 29(30):3960-7. PubMed ID: 21911714
    [Abstract] [Full Text] [Related]

  • 13. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL, Salem R.
    J Vasc Interv Radiol; 2013 Aug 20; 24(8):1123-34. PubMed ID: 23562168
    [Abstract] [Full Text] [Related]

  • 14. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
    Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R.
    Radiology; 2016 May 20; 279(2):630-40. PubMed ID: 26744927
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
    Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.
    Lancet Gastroenterol Hepatol; 2017 Aug 20; 2(8):565-575. PubMed ID: 28648803
    [Abstract] [Full Text] [Related]

  • 16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ.
    BMC Cancer; 2017 Sep 12; 17(1):645. PubMed ID: 28899349
    [Abstract] [Full Text] [Related]

  • 17. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L, Zhao W, Wang M, Hu J, Wang E, Zhao Y, Liu L.
    BMC Gastroenterol; 2018 Sep 04; 18(1):138. PubMed ID: 30180810
    [Abstract] [Full Text] [Related]

  • 18. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS.
    J Gastroenterol Hepatol; 2015 Jul 04; 30(7):1167-74. PubMed ID: 25675849
    [Abstract] [Full Text] [Related]

  • 19. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP.
    World J Gastroenterol; 2017 Nov 21; 23(43):7735-7745. PubMed ID: 29209114
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
    Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH.
    J Hepatol; 2012 Jun 21; 56(6):1336-42. PubMed ID: 22314421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.